Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 6/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29273300 | 1.00 | CHRNB4 (0.40) | CHRNB4CHRNA3CHRNB2CHRNA4L3MBTL3 | |
| SCHEMBL25650396 | 0.81 | CHRNB4 (0.43) | CHRNB4CHRNA3CHRNB2CHRNA4L3MBTL3 | |
| SCHEMBL27455947 | 0.78 | — | — | |
| SCHEMBL14930351 | 0.78 | — | — | |
| SCHEMBL19931584 | 0.78 | — | — | |
| SCHEMBL18270966 | 0.78 | — | — | |
| SCHEMBL8339817 | 0.78 | — | — | |
| SCHEMBL20879730 | 0.78 | — | — | |
| SCHEMBL23925978 | 0.76 | — | — | |
| SCHEMBL14401610 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2025-05-22 | — | — | US | disclosed |
| CN-118339153-A | Heteroaromatic compounds for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2024-07-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | NRAS, KRAS, RB1 | CHRNB4 2410/4885CHRNA3 2982/4885CHRNB2 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.